Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC.

Diabetes Care. 2010 May;33(5):951-7. doi: 10.2337/dc09-1521. Epub 2010 Jan 27.

2.

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C.

Diabetes Care. 2010 Jul;33(7):1509-15. doi: 10.2337/dc09-2191. Epub 2010 Mar 31.

3.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1083-91.

PMID:
15855571
4.

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.

Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Järvinen H, Diamant M.

Diabetes Care. 2011 Sep;34(9):2041-7. doi: 10.2337/dc11-0291.

5.

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Diabet Med. 2012 Dec;29(12):1515-23. doi: 10.1111/j.1464-5491.2012.03699.x.

PMID:
22540883
6.

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1092-100.

PMID:
15855572
7.

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group.

Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.

PMID:
25011946
8.

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

Curr Med Res Opin. 2009 Jan;25(1):65-75. doi: 10.1185/03007990802597951 .

PMID:
19210140
9.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
10.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300. Epub 2010 Dec 6.

PMID:
21138825
11.

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O.

Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23.

PMID:
22216894
13.

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

Diabetes Care. 2006 Nov;29(11):2371-7.

PMID:
17065670
14.

Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Technol Ther. 2012 Jun;14(6):475-84. doi: 10.1089/dia.2011.0278. Epub 2012 Apr 18.

PMID:
22512264
15.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
16.

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Ciccarelli L, D'Angelo A, Fogari E, Maffioli P.

Can J Physiol Pharmacol. 2013 Sep;91(9):724-32. doi: 10.1139/cjpp-2012-0300. Epub 2013 Apr 23.

PMID:
23984793
17.

Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.

van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M.

Diabetes Care. 2011 Feb;34(2):412-7. doi: 10.2337/dc10-1677. Epub 2011 Jan 7.

18.

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M.

Diabetes Care. 2014 Aug;37(8):2159-67. doi: 10.2337/dc13-2760. Epub 2014 May 30. Erratum in: Diabetes Care. 2014 Oct;37(10):2895. Diabetes Care. 2015 Jul;38(7):1393-4.

PMID:
24879836
19.

Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Pharmacotherapy. 2013 Aug;33(8):817-26. doi: 10.1002/phar.1301. Epub 2013 Jun 6.

PMID:
23744726
20.

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.

Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M.

Diabetes Obes Metab. 2010 Dec;12(12):1058-65. doi: 10.1111/j.1463-1326.2010.01251.x.

PMID:
20977576

Supplemental Content

Support Center